Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | PAN domain-containing protein | 0.0308 | 0.4249 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.0308 | 0.4249 | 1 |
Echinococcus multilocularis | enteropeptidase | 0.0495 | 1 | 1 |
Onchocerca volvulus | Arrow homolog | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0171 | 0 | 0.5 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0171 | 0 | 0.5 |
Brugia malayi | Fibulin-1 precursor | 0.0171 | 0 | 0.5 |
Echinococcus granulosus | glycoprotein Antigen 5 | 0.0495 | 1 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0495 | 1 | 1 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0171 | 0 | 0.5 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0171 | 0 | 0.5 |
Echinococcus granulosus | enteropeptidase | 0.0495 | 1 | 1 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0171 | 0 | 0.5 |
Echinococcus multilocularis | glycoprotein Antigen 5 | 0.0495 | 1 | 1 |
Echinococcus multilocularis | Mastin | 0.0495 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | = 10.9 % | Inhibition of human MDR1 expressed in MDCK2 cells assessed as increase of rhodamine 123 uptake at 30 uM up to 240 mins relative to 5 uM tariquidar | ChEMBL. | 25740634 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.